» Articles » PMID: 20572030

Influence of Patients' Preferences and Treatment Site on Cancer Patients' End-of-life Care

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2010 Jun 24
PMID 20572030
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Research suggests that patients' end-of-life (EOL) care is determined primarily by the medical resources available, and not by patient preferences. The authors examined whether patients' desire for life-extending therapy was associated with their EOL care.

Methods: Coping with Cancer is a multisite, prospective, longitudinal study of patients with advanced cancer. Three hundred one patients were interviewed at baseline and followed until death, a median of 4.5 months later. Multivariate analyses examined the influence of patients' preferences and treatment site on whether patients received intensive care or hospice services in the final week of life.

Results: Eighty-three of 301 patients (27.6%) with advanced cancer wanted life-extending therapy at baseline. Patients who understood that their disease was terminal or who reported having EOL discussions with their physicians were less likely to want life-extending care compared with others (23.4% vs 42.6% and 20.7% vs 44.4%, respectively; P≤.003). Patients who were treated at Yale Cancer Center received more intensive care (odds ratio [OR], 3.14; 95% confidence interval [CI], 1.16-8.47) and less hospice services (OR, 0.52; 95% CI, 0.29-0.92) compared with patients who were treated at Parkland Hospital. However, in multivariate analyses that controlled for confounding influences, patients who preferred life-extending care were more likely to receive intensive care (adjusted OR [AOR], 2.91; 95% CI, 1.09-7.72) and were less likely to receive hospice services (AOR, 0.45; 95% CI, 0.26-0.78). Treatment site was not identified as a significant predictor of EOL care.

Conclusions: The treatment preferences of patients with advanced cancer may play a more important role in determining the intensity of medical care received at the EOL than previously recognized. Future research is needed to determine the mechanisms by which patients' preferences for care and treatment site interact to influence EOL care.

Citing Articles

Frequency of anticancer drug use at the end of life: a scoping review.

Szigethy E, Dorantes R, Sugranes M, Madera M, Sola I, Urrutia G Clin Transl Oncol. 2023; 26(1):178-189.

PMID: 37286888 PMC: 10247343. DOI: 10.1007/s12094-023-03234-1.


Does Geography Play a Role in the Receipt of End-of-Life Care for Advanced Cancer Patients? Evidence from an Australian Local Health District Population-Based Study.

Cerni J, Hosseinzadeh H, Mullan J, Westley-Wise V, Chantrill L, Barclay G J Palliat Med. 2023; 26(11):1453-1465.

PMID: 37252775 PMC: 10658736. DOI: 10.1089/jpm.2022.0555.


Quality Indicators for Adolescents and Young Adults With Advanced Cancer: A Modified Delphi Process With Patients, Family Members, and Clinicians.

Mack J, Fisher L, Khalaj A, Altschuler A, Chao C, Kushi L J Pain Symptom Manage. 2023; 66(1):54-61.

PMID: 36933749 PMC: 10330073. DOI: 10.1016/j.jpainsymman.2023.03.005.


Advance care planning (ACP) to promote receipt of value-concordant care: Results vary according to patient priorities.

Prigerson H, Viola M, Maciejewski P, Falzarano F PLoS One. 2023; 18(1):e0280197.

PMID: 36630471 PMC: 9833543. DOI: 10.1371/journal.pone.0280197.


Gender differences in the intention to withhold life-sustaining treatments involving severe dementia for self and on behalf of parent or spouse.

Chen D, Jerng J, Tsai D, Young Y BMC Palliat Care. 2022; 21(1):171.

PMID: 36203170 PMC: 9534740. DOI: 10.1186/s12904-022-01062-8.


References
1.
Prigerson H . Socialization to dying: social determinants of death acknowledgement and treatment among terminally ill geriatric patients. J Health Soc Behav. 1992; 33(4):378-95. View

2.
Fisher E, WENNBERG J, Stukel T, Skinner J, Sharp S, Freeman J . Associations among hospital capacity, utilization, and mortality of US Medicare beneficiaries, controlling for sociodemographic factors. Health Serv Res. 2000; 34(6):1351-62. PMC: 1089085. View

3.
Sharma G, Freeman J, Zhang D, Goodwin J . Continuity of care and intensive care unit use at the end of life. Arch Intern Med. 2009; 169(1):81-6. PMC: 2745737. DOI: 10.1001/archinternmed.2008.514. View

4.
Danis M, Mutran E, Garrett J, Stearns S, Slifkin R, Hanson L . A prospective study of the impact of patient preferences on life-sustaining treatment and hospital cost. Crit Care Med. 1996; 24(11):1811-7. DOI: 10.1097/00003246-199611000-00009. View

5.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View